Targeting antitumor T cell as well as preparation method and application thereof

Abstract

The invention provides a targeting antitumor T cell. The targeting antitumor T cell comprises an IL13Ralpha2-targeting chimeric antigen receptor CAR-IL13Ralpha2 and / or an HER2-targeting chimeric antigen receptor CAR-HER2, wherein the CAR-IL13Ralpha2 comprises amino acid sequences of an IL13Ralpha2-targeting single chain antibody, an extracellular hinge region, a transmembrane region and an intracellular signal region, which are sequentially connected from an amino terminal to a carboxyl terminal, and the CAR-HER2 comprises amino acid sequences of an HER2-targeting single chain antibody, an extracellular hinge region, a transmembrane region and an intracellular signal region, which are sequentially connected from the amino terminal to the carboxyl terminal. The targeting antitumor T cell can efficiently recognize and kill tumor cells of surface IL13Ralpha2 and / or HER2 positive antigens, can effectively overcome immune escape of tumor cells, and has lasting tumor killing effects. The invention also provides a preparation method and an application of the targeting antitumor T cell.

Description

technical field [0001] The invention relates to the field of medical biology, in particular to a targeted anti-tumor T cell and its preparation method and application. Background technique [0002] Glioma, short for glioma, is the most common malignant tumor of the central nervous system (CNS), originating from glial cells. Glioma is a tumor with strong invasiveness and high recurrence rate. Due to its invasive growth, surgical treatment is difficult to remove all tumor cells. Even if it is supplemented with radiotherapy and chemotherapy, recurrence is still inevitable. [0003] Chimeric Antigen Receptor T-Cell Immunotherapy (CAR-T) technology developed in recent years is one of the more effective treatments for malignant tumors. CAR-T technology injects a new solution for adoptive cellular immunotherapy by utilizing the targeting, killing activity and persistence of T cells expressing tumor-specific chimeric antigen receptors through genetic modification technology. Howev...

AI Technical Summary

Problems solved by technology

However, the current application of CAR-T technology is still limited to hematological tumors, and there is no relevant research on the application of tumor cells such as glioma; at the same time, the loss of target tumor antigens on tumor cells often occurs during the application of CAR-T technology , endocytosis, and mutation, causing CAR-T cells to fail to recognize and activate

Images